文献速递中枢神经肿瘤放疗放疗物理与技术

胶质母细胞瘤患者的假性进展与真性进展:多方法分析

Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis.
PubMed 文献 · Radiother Oncol · 2023-01-24

该研究基于III期SpectroGlio试验中46例放疗后6个月内怀疑进展的胶质母细胞瘤患者,采用临床数据、弥散/灌注加权成像及三维磁共振波谱成像的多方法分析鉴别真性进展与假性进展。结果显示假性进展组中位总生存期高于真性进展组(25.2 vs 20.3个月,p=0.0092),真性进展组乳酸/N-乙酰天冬氨酸和胆碱/肌酸比值更高,多变量分析中肿瘤体积是唯一保留的预测因子(p=0.028)。

要点

  • 放疗后6个月内怀疑进展的46例中,28例为假性进展,18例为真性进展。
  • 假性进展组中位总生存期25.2个月 vs 真性进展组20.3个月(p=0.0092)。
  • 真性进展组乳酸/N-乙酰天冬氨酸比值1.2 vs 假性进展组0.5(p=0.006)。

核心结论

  • 三个波谱比值可用于鉴别假性进展与真性进展,复发时肿瘤体积是多变量分析中最具预测性的因素,假性进展组总生存期高于真性进展组。

研究设计与样本

  • 研究纳入III期SpectroGlio试验(NCT01507506)的180例患者,其中46例在放疗后6个月内怀疑进展。
  • 采用多方法分析,结合临床数据、弥散加权成像、灌注加权成像和三维磁共振波谱成像。
  • 提取胆碱/肌酸、胆碱/N-乙酰天冬氨酸和乳酸/N-乙酰天冬氨酸比值,计算表观扩散系数和脑血容量图。
  • 在复发时收集表观扩散系数、相对脑血容量值和肿瘤体积。
  • 使用Mann-Whitney检验评估真性进展与假性进展的差异,p值经Bonferroni校正。

主要发现

  • 怀疑进展的患者在首次MRI后1个月接受新的MRI扫描,其中28例分类为假性进展,18例为真性进展。
  • 中位随访41个月后,假性进展组中位总生存期高于真性进展组(25.2 vs 20.3个月;p=0.0092)。
  • 真性进展组乳酸/N-乙酰天冬氨酸比值高于假性进展组(1.2 vs 0.5;p=0.006)。
  • 真性进展组胆碱/肌酸比值高于假性进展组(3 vs 2.2;p=0.021)。
  • 多变量回归分析后,肿瘤体积是真性进展与假性进展的最显著预测因子,且是模型中唯一保留的变量(p=0.028)。

关键数值与推荐

  • 乳酸/N-乙酰天冬氨酸比值:真性进展组1.2 vs 假性进展组0.5(p=0.006)。
  • 胆碱/肌酸比值:真性进展组3 vs 假性进展组2.2(p=0.021)。
  • 肿瘤体积在多变量分析中预测真性进展与假性进展的p=0.028。
  • 假性进展组中位总生存期25.2个月 vs 真性进展组20.3个月(p=0.0092)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To investigate the feasibility of using a multiapproach analysis combining clinical data, diffusion- and perfusion-weighted imaging, and 3D magnetic resonance spectroscopic imaging to distinguish true tumor progression (TP) from pseudoprogression (PSP) in patients with glioblastoma. MATERIALS AND METHODS: Progression was suspected within 6 months of radiotherapy in 46 of the 180 patients included in the Phase-III SpectroGlio trial (NCT01507506). Choline/creatine (Cho/Cr), choline/N-acetyl aspartate (Cho/NAA) and lactate/N-acetyl aspartate (Lac/NAA) ratios were extracted. Apparent diffusion coefficient (ADC) and cerebral blood volume (CBV) maps were calculated. ADC, relative CBV values and tumor volume (TV) were collected at relapse. Differences between TP and PSP were evaluated using Mann-Whitney tests, and p values were adjusted with Bonferroni correction. RESULTS: Patients with suspected progression underwent a new MRI scan 1 month after the first one. Of these, 28 were classified as PSP, and 18 as TP. After a median follow-up of 41 months, median overall survival was higher in PSP than in TP (25.2 vs 20.3 months; p = 0.0092). Lac/NAA and Cho/Cr ratios were higher in TP than in PSP (1.2 vs 0.5; p = 0.006; and 3 vs 2.2; p = 0.021). After multivariate regression analysis, TV was the most significant predictor of TP vs PSP, and the only one retained in the model (p = 0.028). CONCLUSION: Three spectroscopic ratios could be used to differentiate PSP from TP. TV at relapse was the most predictive factor in the multivariate analysis, and overall survival was higher in PSP than in TP.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Sidibe I, Tensaouti F, Gilhodes J, et al. Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis. Radiother Oncol. 2023. PMID: 36706959. doi:10.1016/j.radonc.2023.109486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。